Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Timolumab - Acorda Therapeutics

Drug Profile

Timolumab - Acorda Therapeutics

Alternative Names: Anti-VAP-1 monoclonal antibody fully human; BTT-1023; Fully human anti-VAP-1 monoclonal antibody; Fully human anti-vascular adhesion protein 1 monoclonal antibody; SI-3106

Latest Information Update: 31 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biotie Therapies Corp.
  • Developer Acorda Therapeutics; Biotie Therapies Corp.; Seikagaku Corporation
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action AOC3 protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Primary sclerosing cholangitis
  • No development reported Inflammation; Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 31 Jul 2019 Phase II development is ongoing United Kingdom for Primary sclerosing cholangitis (Acorda Therapeutics pipeline - July 2019)
  • 27 Feb 2019 Acorda Therapeutics and the University of Birmingham have patent protection for composition of matter and methods of use
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top